Microsoft actually had some good news for investors today, but its stock is still losing ground.

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.

(Drazen Zigic/iStock/Getty Images Plus) Around 1 in 5 US adults are thought to struggle with sleep health, and for many of us ...

Treasury Secretary Scott Bessent found himself on the defensive after claiming that "groceries are going down" — only to be ...

Margot Kuylen and Dan Wellings consider the results of the Health Insight Survey and finds that while waiting times have ...

In a commanding display of cricketing dominance, India secured a massive innings-and-300-run victory over Afghanistan in ...

Position groups worth monitoring as minicamp begins.

A toothbrush, some toothpaste and a few minutes of care can prevent a life‑threatening infection. That’s rare in modern ...

For 14 years, patient access to TAVR has been restricted for Medicare beneficiaries under a Coverage with Evidence ...

Missoula County filed two deliberate homicide charges in 1990 nursing home killings after new DNA evidence linked suspect Nickie Dean Gardiner to both victims.

Understanding the Significance of June 10, 2026June 10, 2026, arrives at a time when many people are seeking clarity in ...